Approval Package for:

APPLICATION NUMBER: 205103Orig1s000

Trade Name: Yosprala delayed release tablets

Generic or Proper Name: aspirin 81 mg/omeprazole 40 mg, and aspirin 325 mg/omeprazole 40 mg

Sponsor: Aralez Pharmaceuticals R&D Inc.

Approval Date: September 14, 2016

Indication: Provides for the use of Yosprala delayed-release tablets (aspirin 81 mg/omeprazole 40 mg, and aspirin 325 mg/omeprazole 40 mg) for the following:

• Secondary prevention of cardiovascular and cerebrovascular events in patients at risk of developing aspirin associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers.

• Decreasing the risk of developing aspirin associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers.
<table>
<thead>
<tr>
<th>Reviews / Information Included in this NDA Review.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
</tr>
<tr>
<td>Other Action Letters</td>
</tr>
<tr>
<td>Labeling</td>
</tr>
<tr>
<td>REMS</td>
</tr>
<tr>
<td>Summary Review</td>
</tr>
<tr>
<td>Officer/Employee List</td>
</tr>
<tr>
<td>Office Director Memo</td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
</tr>
<tr>
<td>Clinical Review(s)</td>
</tr>
<tr>
<td>Product Quality Review(s)</td>
</tr>
<tr>
<td>Non-Clinical Review(s)</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
</tr>
<tr>
<td>Clinical Microbiology / Virology Review(s)</td>
</tr>
<tr>
<td>Clinical Pharmacology Review(s)</td>
</tr>
<tr>
<td>Other Reviews</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:

205103Orig1s000

APPROVAL LETTER
NDA 205103

Aralez Pharmaceuticals R&D Inc.
Attention: Peggy Berry
Regulatory Lead
400 Alexander Park Drive
Princeton, NJ 08540-6539

Dear Ms. Berry:

Please refer to your New Drug Application (NDA) dated and received March 25, 2013, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Yosprala (aspirin 81 mg/omeprazole 40 mg, and aspirin 325 mg/omeprazole 40 mg) delayed-release tablets.

The March 14, 2016, submission constituted a complete response to our December 16, 2014 action letter.

This new drug application provides for the use of Yosprala delayed-release tablets (aspirin 81 mg/omeprazole 40 mg, and aspirin 325 mg/omeprazole 40 mg) for the following:

- Secondary prevention of cardiovascular and cerebrovascular events in patients at risk of developing aspirin associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers.

- Decreasing the risk of developing aspirin associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As, available at
The SPL will be accessible via publicly available labeling repositories.

**CARTON AND IMMEDIATE CONTAINER LABELS**

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels and submitted carton and immediate container labels, except with the revisions listed above, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Carton and Container Labels for approved NDA 205103.” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric studies requirement for this application because necessary studies are impossible or highly impracticable.

**POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B**

We remind you of your postmarketing commitments:
3111-1 Conduct an in vitro study to characterize and quantify the degradants of the immediate release omeprazole of Yosprala at various pHs (i.e., pH 1, 1.5, 2, 2.5, 3, 3.5, 4) following a minimum of 1 hour of exposure at 37°C, and evaluate the differences in the profiles across pHs. Submit the chromatograms and a summary of quantitative data generated during the study.

The timetable you submitted on August 30, 2016, states that you will conduct this trial according to the following schedule:

- Final Protocol Submission: 01/2017
- Study Completion: 04/2017
- Final Report Submission: 06/2017

3111-2 Conduct a clinical PK trial evaluating the systemic exposures of the omeprazole degradants that are shown to be present at a higher level at pH <3.0 compared to higher pHs in the in vitro studies (PMC #3111-1). This trial will include both Yosprala and the reference product for the omeprazole component of Yosprala. Compare the individual omeprazole degradant exposures between the two products.

The timetable you submitted on August 30, 2016, states that you will conduct this study according to the following schedule:

- Final Protocol Submission: 11/2017
- Study Completion: 03/2018
- Final Report Submission: 06/2018

Submit clinical protocols to your IND 78747 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “Postmarketing Commitment Protocol,” “Postmarketing Commitment Final Report,” or “Postmarketing Commitment Correspondence.”

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert, Medication Guide, and patient PI (as applicable) to:
Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call CAPT Mimi T. Phan, Regulatory Project Manager, at (301) 796-5408.

Sincerely,

{See appended electronic signature page}

Donna Griebel, M.D.
Director
Division of Gastroenterology and Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure(s):
Content of Labeling
Carton and Container Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DONNA J GRIEBEL
09/14/2016